The global next-generation cancer therapeutics market size is evaluated at USD 92.54 billion in 2025 and is forecasted to hit around USD 175.20 billion by 2034, growing at a CAGR of 7.35% from 2025 to 2034. The North America market size was accounted at USD 35.34 billion in 2024 and is expanding at a CAGR of 7.48% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next-Generation Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next-Generation Cancer Therapeutics Market, by Therapy Type
8.1.1. Targeted Therapy (Small Molecule Inhibitors)
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Gene Therapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Cell Therapy (e.g., TILs, NK cells)
8.1.4.1. Market Revenue and Forecast
8.1.5. Antibody-Drug Conjugates (ADCs)
8.1.5.1. Market Revenue and Forecast
8.1.6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
8.1.6.1. Market Revenue and Forecast
9.1. Next-Generation Cancer Therapeutics Market, by Cancer Type
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Breast Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast
9.1.4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
9.1.4.1. Market Revenue and Forecast
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast
9.1.6. Brain Cancer (e.g., GBM)
9.1.6.1. Market Revenue and Forecast
9.1.7. Pan-Tumor (Tumor-agnostic therapies)
9.1.7.1. Market Revenue and Forecast
10.1. Next-Generation Cancer Therapeutics Market, by Modality
10.1.1. Monotherapy
10.1.1.1. Market Revenue and Forecast
10.1.2. Combination Therapy
10.1.2.1. Market Revenue and Forecast
11.1. Next-Generation Cancer Therapeutics Market, by Route of Administration
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast
11.1.2. Oral
11.1.2.1. Market Revenue and Forecast
11.1.3. Intratumoral / Localized
11.1.3.1. Market Revenue and Forecast
11.1.4. Subcutaneous
11.1.4.1. Market Revenue and Forecast
12.1. Next-Generation Cancer Therapeutics Market, by Mechanism of Action
12.1.1. Immune Activation (Checkpoint Inhibition)
12.1.1.1. Market Revenue and Forecast
12.1.2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
12.1.2.1. Market Revenue and Forecast
12.1.3. DNA Damage Response Modulators (e.g., PARP inhibitors)
12.1.3.1. Market Revenue and Forecast
12.1.4. Tumor Microenvironment Modulation
12.1.4.1. Market Revenue and Forecast
12.1.5. Apoptosis Induction
12.1.5.1. Market Revenue and Forecast
13.1. Next-Generation Cancer Therapeutics Market, by End-User
13.1.1. Specialized Cancer Hospitals
13.1.1.1. Market Revenue and Forecast
13.1.2. Academic & Research Institutes
13.1.2.1. Market Revenue and Forecast
13.1.3. Ambulatory Infusion Centers
13.1.3.1. Market Revenue and Forecast
13.1.4. Discrete
13.1.4.1. Market Revenue and Forecast
13.1.5. Homecare (for oral or SC delivery)
13.1.5.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapy Type
14.1.2. Market Revenue and Forecast, by Cancer Type
14.1.3. Market Revenue and Forecast, by Modality
14.1.4. Market Revenue and Forecast, by Route of Administration
14.1.5. Market Revenue and Forecast, by Mechanism of Action
14.1.6. Market Revenue and Forecast, by End-User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapy Type
14.1.7.2. Market Revenue and Forecast, by Cancer Type
14.1.7.3. Market Revenue and Forecast, by Modality
14.1.7.4. Market Revenue and Forecast, by Route of Administration
14.1.8. Market Revenue and Forecast, by Mechanism of Action
14.1.8.1. Market Revenue and Forecast, by End-User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapy Type
14.1.9.2. Market Revenue and Forecast, by Cancer Type
14.1.9.3. Market Revenue and Forecast, by Modality
14.1.9.4. Market Revenue and Forecast, by Route of Administration
14.1.10. Market Revenue and Forecast, by Mechanism of Action
14.1.11. Market Revenue and Forecast, by End-User
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapy Type
14.2.2. Market Revenue and Forecast, by Cancer Type
14.2.3. Market Revenue and Forecast, by Modality
14.2.4. Market Revenue and Forecast, by Route of Administration
14.2.5. Market Revenue and Forecast, by Mechanism of Action
14.2.6. Market Revenue and Forecast, by End-User
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapy Type
14.2.8.2. Market Revenue and Forecast, by Cancer Type
14.2.8.3. Market Revenue and Forecast, by Modality
14.2.9. Market Revenue and Forecast, by Route of Administration
14.2.10. Market Revenue and Forecast, by Mechanism of Action
14.2.10.1. Market Revenue and Forecast, by End-User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapy Type
14.2.11.2. Market Revenue and Forecast, by Cancer Type
14.2.11.3. Market Revenue and Forecast, by Modality
14.2.12. Market Revenue and Forecast, by Route of Administration
14.2.13. Market Revenue and Forecast, by Mechanism of Action
14.2.14. Market Revenue and Forecast, by End-User
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapy Type
14.2.15.2. Market Revenue and Forecast, by Cancer Type
14.2.15.3. Market Revenue and Forecast, by Modality
14.2.15.4. Market Revenue and Forecast, by Route of Administration
14.2.16. Market Revenue and Forecast, by Mechanism of Action
14.2.16.1. Market Revenue and Forecast, by End-User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapy Type
14.2.17.2. Market Revenue and Forecast, by Cancer Type
14.2.17.3. Market Revenue and Forecast, by Modality
14.2.17.4. Market Revenue and Forecast, by Route of Administration
14.2.18. Market Revenue and Forecast, by Mechanism of Action
14.2.18.1. Market Revenue and Forecast, by End-User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapy Type
14.3.2. Market Revenue and Forecast, by Cancer Type
14.3.3. Market Revenue and Forecast, by Modality
14.3.4. Market Revenue and Forecast, by Route of Administration
14.3.5. Market Revenue and Forecast, by Mechanism of Action
14.3.6. Market Revenue and Forecast, by End-User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapy Type
14.3.7.2. Market Revenue and Forecast, by Cancer Type
14.3.7.3. Market Revenue and Forecast, by Modality
14.3.7.4. Market Revenue and Forecast, by Route of Administration
14.3.8. Market Revenue and Forecast, by Mechanism of Action
14.3.9. Market Revenue and Forecast, by End-User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapy Type
14.3.10.2. Market Revenue and Forecast, by Cancer Type
14.3.10.3. Market Revenue and Forecast, by Modality
14.3.10.4. Market Revenue and Forecast, by Route of Administration
14.3.11. Market Revenue and Forecast, by Mechanism of Action
14.3.11.1. Market Revenue and Forecast, by End-User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapy Type
14.3.12.2. Market Revenue and Forecast, by Cancer Type
14.3.12.3. Market Revenue and Forecast, by Modality
14.3.12.4. Market Revenue and Forecast, by Route of Administration
14.3.12.5. Market Revenue and Forecast, by Mechanism of Action
14.3.12.6. Market Revenue and Forecast, by End-User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapy Type
14.3.13.2. Market Revenue and Forecast, by Cancer Type
14.3.13.3. Market Revenue and Forecast, by Modality
14.3.13.4. Market Revenue and Forecast, by Route of Administration
14.3.13.5. Market Revenue and Forecast, by Mechanism of Action
14.3.13.6. Market Revenue and Forecast, by End-User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapy Type
14.4.2. Market Revenue and Forecast, by Cancer Type
14.4.3. Market Revenue and Forecast, by Modality
14.4.4. Market Revenue and Forecast, by Route of Administration
14.4.5. Market Revenue and Forecast, by Mechanism of Action
14.4.6. Market Revenue and Forecast, by End-User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapy Type
14.4.7.2. Market Revenue and Forecast, by Cancer Type
14.4.7.3. Market Revenue and Forecast, by Modality
14.4.7.4. Market Revenue and Forecast, by Route of Administration
14.4.8. Market Revenue and Forecast, by Mechanism of Action
14.4.9. Market Revenue and Forecast, by End-User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapy Type
14.4.10.2. Market Revenue and Forecast, by Cancer Type
14.4.10.3. Market Revenue and Forecast, by Modality
14.4.10.4. Market Revenue and Forecast, by Route of Administration
14.4.11. Market Revenue and Forecast, by Mechanism of Action
14.4.12. Market Revenue and Forecast, by End-User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapy Type
14.4.13.2. Market Revenue and Forecast, by Cancer Type
14.4.13.3. Market Revenue and Forecast, by Modality
14.4.13.4. Market Revenue and Forecast, by Route of Administration
14.4.13.5. Market Revenue and Forecast, by Mechanism of Action
14.4.13.6. Market Revenue and Forecast, by End-User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapy Type
14.4.14.2. Market Revenue and Forecast, by Cancer Type
14.4.14.3. Market Revenue and Forecast, by Modality
14.4.14.4. Market Revenue and Forecast, by Route of Administration
14.4.14.5. Market Revenue and Forecast, by Mechanism of Action
14.4.14.6. Market Revenue and Forecast, by End-User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapy Type
14.5.2. Market Revenue and Forecast, by Cancer Type
14.5.3. Market Revenue and Forecast, by Modality
14.5.4. Market Revenue and Forecast, by Route of Administration
14.5.5. Market Revenue and Forecast, by Mechanism of Action
14.5.6. Market Revenue and Forecast, by End-User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapy Type
14.5.7.2. Market Revenue and Forecast, by Cancer Type
14.5.7.3. Market Revenue and Forecast, by Modality
14.5.7.4. Market Revenue and Forecast, by Route of Administration
14.5.8. Market Revenue and Forecast, by Mechanism of Action
14.5.8.1. Market Revenue and Forecast, by End-User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapy Type
14.5.9.2. Market Revenue and Forecast, by Cancer Type
14.5.9.3. Market Revenue and Forecast, by Modality
14.5.9.4. Market Revenue and Forecast, by Route of Administration
14.5.9.5. Market Revenue and Forecast, by Mechanism of Action
14.5.9.6. Market Revenue and Forecast, by End-User
15.1. Roche Holding AG
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Bristol Myers Squibb
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Merck & Co., Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Pfizer Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. AstraZeneca plc
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Eli Lilly and Company
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Gilead Sciences, Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Seagen Inc. (Pfizer)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Amgen Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description